Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2004

View Archived Issues

Promising second generation vascular targeting agent

Apigenin inhibits proliferation and induces apoptosis in prostatic stromal cells

DP-109, a lipophilic metal chelator, reduces amyloid pathology in AD model

MorphoSys achieves fourth milestone in Centocor cooperation

Phase II study of Topiglan fails to meet primary clinical endpoints

Abbott and Orion expand licensing agreement for injectable levosimendan

Metoprolol increases compliance and improves tolerability of sibutramine in obese patients

Anastrozole reported effective in preventing testosterone-induced gynecomastia

Good safety and pharmacokinetic profile of intranasal butorphanol given using a single-dose sprayer

DailyDrugNews and LifeSci Channel announce highlights from the 3rd Annual Global Biotech Forum

Kureha presents new CCR5 antagonists for HIV and other viral infections

New HDAC inhibitors isolated from Pseudomonas cultures

Novel antibacterial agents prepared and tested by Bayer team

Alcon claims new 5-HT2 receptor agonists and their use as IOP lowering agents

Novel FAAH inhibitors discovered by Sanofi-Synthelabo scientists

Two series of PDE4 inhibitors and their use reported by Altana Pharma

New CCR4 antagonists covered by BMS patent

Inhibition of presenilin function may be detrimental in Alzheimer's disease

Preclinical studies evaluate EOquin in combination with radiation therapy

Nicotine may boost regenerative abilities of stem cells in heart failure patients

Micrologix to acquire MitoKor

Scottish government grant supports anti-CD55 antibody development at Viragen

New phase I study evaluates APF-530 for CINV

Phase II trial studies Xcellerated T Cells for multiple myeloma

Eurand and U. of Urbino enter anticancer research agreement

INO-4995 shows potency in cystic fibrosis mouse NPD model

E.U. launch for Amplicor Human Papillomavirus test kit

Discovery of SSX-2 offers new target for development of melanoma vaccine

Extensive data presented on AZD-2171, a potent VEGF receptor tyrosine kinase inhibitor

Suppression of osteolytic bone metastasis by c-Fms tyrosine kinase inhibitor Ki-20227

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...